Effectiveness of L-carnitine Supplementation to Sertraline for Treatment of Major Depressive Disorder: A Double-blind Randomized Placebo-controlled Trial

Author:

Ramezani Azadeh1,Kheirkhah Farzan1,Zabihi Ebrahim2,Shirafkan Hoda1,Moudi Sussan1

Affiliation:

1. Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran,

2. Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran,

Abstract

Objectives: Despite the various treatment approaches proposed for major depressive disorder (MDD), the right treatment protocol for different patients is not the same. Supplementation of L-carnitine to antidepressants has been recommended in some studies; however, different results have been reported. This study aimed to evaluate the effectiveness of adding L-carnitine to sertraline in the treatment of patients diagnosed with MDD. Material and Methods: This double-blind randomized controlled trial was conducted on 60 patients with MDD. The severity of the depressive disorder, as the primary research outcome, was assessed using the Beck depression inventory. The intervention group received 1000 mg of daily L-carnitine oral capsule along with 100 mg of sertraline; and the control group received a placebo (oral capsule containing 1000 mg of starch), along with 100 mg of sertraline every day. The primary outcome was assessed at baseline, the 3rd, and the 6th week. Results: Although depression score decreased in both groups over time, the difference between the two groups was not significant (P = 0.634). Three patients reported adverse side effects; however, the difference between the two groups was not significant (P = 0.554). Conclusion: Supplementation of L-carnitine to sertraline in patients with MDD did not show a significant effect on the improvement of depression severity.

Publisher

Scientific Scholar

Subject

General Medicine

Reference23 articles.

1. Prevalence of major depressive disorder in the general population of Iran: A systematic review and meta-analysis;Gharraee;Med J Islam Repub Iran,2019

2. Depression;World Health Organization;WHO Fact Sheets,2021

3. International Statistical Classification of Diseases and Related Health Problems;World Health Organization,2016

4. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic;Santomauro;Lancet,2021

5. Global burden of 369 diseases and injuries in 204 countries and territories: A systematic analysis for the global burden of disease study 2019;Vos;Lancet,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3